1. Codington JF, Finn DM (1983) Cell-surface macromolecular and morphological changes related to allotransplantability in the TA3 tumor. In: Nowotny A (ed) Biomembranes, vol 11. Plenum Press, New York, p 207
2. Ding L, Lalani E, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Taylor-Papadimitriou J, Longenecker BM (1992) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucine gene: Effect of immunization of the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 36: 9
3. Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-Ha). Cancer Res 51: 1170
4. Fung PYS, Madej M, Koganty R, Longenecker BM (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50: 4308
5. Hanisch FG, Uhlenbruek G, Egge H, Peter-Katalinic J (1989) A B72.3 second-generation monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Galβ(1→3)[NeuAcα(2→6)] GalNAc. J Biol Chem 370: 21